Capital Increase Reduced to 13.99B KRW
젬백스
082270
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2767
Risk-adjusted indicator based on 2767 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEUTRAL
Key Numbers
- • New Shares (Amended): 1,221,384 Shares
- • Funding Amount (Amended): 13,999,964,888 KRW
- • Original New Shares: 1,384,439 Shares
- • Original Funding Amount: 15,999,961,523 KRW
- • R&D and Raw Material Costs (Amended): 7,000M KRW each for 2026
AI Analysis Summary
GemVax & KAEL Co.,Ltd. has amended its paid-in capital increase, reducing the number of new common shares from 1,384,439 to 1,221,384 and the total funding from 15.99 billion KRW to 13.99 billion KRW. The funds, primarily for operating capital, will be allocated to bio business R&D (7,000M KRW) and environmental business raw materials (7,000M KRW) in 2026. The third-party allocation includes From AI Co., Ltd. (822,012 shares) and several individuals, with all allocated shares subject to a one-year lock-up period. The reduction in funding slightly mitigates dilution but the overall impact remains neutral as the capital is for operational expenses.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.